Edition:
United States

pSivida Corp (PSDV.OQ)

PSDV.OQ on NASDAQ Stock Exchange Global Market

1.10USD
16 Feb 2018
Change (% chg)

$0.01 (+0.92%)
Prev Close
$1.09
Open
$1.09
Day's High
$1.13
Day's Low
$1.08
Volume
39,088
Avg. Vol
70,356
52-wk High
$2.45
52-wk Low
$0.93

Select another date:

Wed, Feb 7 2018

BRIEF-Psivida Corp Reports Q2 Loss Per Share $0.13

* REPORTS SECOND QUARTER FY2018 RESULTS; CONTINUES TO ACHIEVE MILESTONES AND TIMELINES

BRIEF-Psivida's Second Phase 3 Study For Durasert Three-Year Treatment For Posterior Segment Uveitis Maintains Positive Efficacy And Safety Profile At 12 Months

* PSIVIDA'S SECOND PHASE 3 STUDY FOR DURASERT™ THREE-YEAR TREATMENT FOR POSTERIOR SEGMENT UVEITIS MAINTAINS POSITIVE EFFICACY AND SAFETY PROFILE AT 12 MONTHS

BRIEF-pSivida Submits New Drug Application For Durasert Three-Year Treatment For Posterior Segment Uveitis To The U.S. FDA

* PSIVIDA SUBMITS NEW DRUG APPLICATION (NDA) FOR DURASERT™ THREE-YEAR TREATMENT FOR POSTERIOR SEGMENT UVEITIS TO THE U.S. FDA

BRIEF-Psivida Granted Waiver By The FDA For New Drug Application Filing Fee

* PSIVIDA GRANTED WAIVER BY THE FDA FOR NEW DRUG APPLICATION FILING FEE

BRIEF-HSS And PSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data

* HSS AND PSIVIDA REPORT POSITIVE PHASE 1 KNEE OSTEOARTHRITIS PAIN STUDY DATA

BRIEF-pSivida reports Q1 loss per share of $0.15

* Q1 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Nicox and pSivida enter strategic collaboration agreement

* REG-NICOX AND PSIVIDA ENTER STRATEGIC COLLABORATION AGREEMENT TO DEVELOP SUSTAINED RELEASE DRUG TO LOWER INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA

BRIEF-Nicox and pSivida enter collaboration agreement to develop sustained release drug for glaucoma patients​

* Nicox-Co and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma​

BRIEF-pSivida partners with global pharmaceuticals company to develop sustained release formulations of glaucoma drugs

* pSivida partners with global pharmaceuticals company to develop sustained release formulations of glaucoma drugs

BRIEF-pSivida Corp reports Q4 loss per share $0.16

* pSivida Corp achieves significant milestones throughout fy 2017; reports fourth quarter and fiscal 2017 results

Select another date: